Table 4.
Gaps of control capacity and diagnostic/drug development presented in total 4 consultation meetings
| Diseases | No. | Gap from consultation |
|---|---|---|
| Malaria |
1 |
Need new diagnosis method for asymptomatic patients |
| 2 |
Need innovative and safer drugs |
|
| 3 |
Lack of techniques to distinguish abroad-imported cases from indigenous cases |
|
| 4 |
Difficulty in finding asymptomatic patients |
|
| 5 |
Need new surveillance system for pre-elimination period |
|
| 6 |
More focus on the continuously increasing imported cases |
|
| Schistosomiasis japonica |
1 |
Need higher sensitive antigen testing |
| 2 |
Need new drug which can prevent reinfection |
|
| 3 |
Need new molluscicide with less negative impact on the environment and biodiversity |
|
| 4 |
Difficulty in testing for a moving population |
|
| 5 |
Need innovative surveillance-response approaches system |
|
| 6 |
Difficulty in controlling for more than 40 hosts |
|
| Echinococcosis |
1 |
Need effective drug for short-term treatment |
| 2 |
Need financial support for hygiene and sanitation in epidemic areas |
|
| 3 |
Need long-acting antihelmintic implants or drugs to control dog infection |
|
| 4 |
Need effective vaccine for people in epidemic areas |
|
| 5 |
Need more sensitive serological test for field survey |
|
| 6 | Control of the wildlife transmission cycles of E multilocularis is difficult |